

TABLE OF CONTENTS

1. INTRODUCTION	1
2. REVIEW OF LITERATURE	8
2.1 Cardiometabolic disorders.....	8
2.1.1 History and epidemiology of CMets	8
2.1.2 Major components of Cardiometabolic disorders	9
2.2 Role of Hypertension as the initiator of CMets.....	10
2.2.1 Hemostatic control of blood pressure and hypertension	10
2.3 Role of RAAS in hypertension and Mets.....	11
2.3.1 Renin Angiotensin Aldosterone System (RAAS): activation, signalling and receptor function.....	11
2.3.1.1 The Angiotensin receptor type 1 (AT ₁ receptor).....	12
2.3.1.2 Signaling pathways	13
2.4 Autonomic Nervous System and blood pressure control	13
2.4.1 Autonomic Dysfunction in Early Hypertensive Phases.....	14
2.4.1.1 Parasympathetic nervous system alteration in hypertension.....	14
2.4.1.2 Sympathetic nervous system association with hypertension and CMets.....	14
2.5 Cross talks between RAAS and the α -Adrenergic system	15
2.6 Insulin resistance: Major culprit for Cardiometabolic disorder.....	18
2.6.1 Insulin signalling	18
2.6.2 Insulin resistance and Renin Angiotensin Aldosterone System	18
2.6.3 Insulin resistance and Sympathetic nervous system.....	20
2.7 Endothelial dysfunction and Vascular reactivity.....	21
2.8 Dyslipidemias in the Metabolic Syndrome	21
2.9 Management of hypertension and cardiometabolic disorders	22
2.9.1 Lifestyle modification	22
2.9.2 Pharmacological approaches	23
2.9.2.1 Network Pharmacology: Polypill and combination therapy approach	23
2.10 The concept of Designed Multiple Ligands	24
2.10.1 Dual blockers involving AT ₁ R or α_1 -adreno receptor blockade.....	25
2.11 Hypercoagulation and cardiometabolic disorders	27
2.11.1 Haemostasis of blood flow and Blood clotting cascade	28
2.12 Role of Factor Xa in haemostasis and pathophysiology of CVD.....	30

2.12.1	Structure and activation of Factor Xa.....	30
2.12.2	Pleotropic effect of Factor Xa and thrombin via Plasminogen Activated Receptors (PARs)	31
2.12.3	FXa: promising target for anticoagulant therapy	32
2.12.4	FXa vs. FIIa inhibition - Which one is better?	32
2.13	Management of hypercoagulable events	33
2.13.1	Anticoagulants: Utilization and drawbacks of current therapy	33
2.13.2	Novel Anticoagulant drugs.....	34
3.	AIM AND OBJECTIVES	36
3.1	Aim.....	36
3.2	Objectives for designed multitargeted ligands in hypertension and cardiometabolic disorders	36
3.3	Objectives for novel Factor Xa (FXa) inhibitors for anticoagulant and antithrombotic activity	36
4.	MATERIAL AND METHODS	38
4.1	Material	38
4.2	Animals	38
4.3	Methods for screening and evaluation of designed multitargeted ligands in hypertension and cardiometabolic disorders	39
4.3.1	Functional antagonism assay using isolated rat thoracic aorta preparation.....	39
4.3.2	Docking study of compound (18) and (24) with α_1 and AT ₁ receptor	40
4.3.3	<i>In-vivo</i> pressor response by invasive blood pressure measurement of compound (18) and (24) 40	
4.3.3.1	<i>In-vivo</i> pressor response evaluation under unmasked condition.....	40
4.3.3.2	<i>In-vivo</i> pressor response evaluation under masked conditions	41
4.3.4	Cytotoxicity assay of compound (18) and (24) on HEK 293 cell culture	41
4.3.5	Physiochemical properties and Drug-likeness prediction of compound (18) and (24)	42
4.3.6	ADME analysis and toxicity prediction of compound (18) and (24)	42
4.3.7	Acute toxicity study of compound (18) and (24) according to OECD guidelines ..	43
4.3.8	Evaluation of antihypertensive activity of compound (18) and (24) in unilateral nephrectomy (UNX) and DOCA salt induced hypertension in rats	43

4.3.9 Evaluation of antihypertensive activity of compound (18) and (24) in L-Nitro Arginine Methyl Ester (L-NAME) induced hypertension.....	45
4.3.10 Collection, processing and storage of samples.....	45
4.3.10.1 Collection of blood	45
4.3.10.2 Collection of urine	46
4.3.11 Measurement of Hemodynamic parameters.....	46
4.3.11.1 Invasive blood pressure measurement	46
4.3.12 Endothelial dysfunction.....	46
4.3.13 Blood and Urine parameters.....	47
4.3.13.1 Blood plasma parameters.....	47
4.3.13.1.1 Tumor necrosis factor- α (TNF- α).....	47
4.3.13.1.2 Interleukin-6 (IL-6).....	48
4.3.13.1.3 Renin.....	49
4.3.13.1.4 Estimation of Protein kinase C (PKC) and phospho-Akt (p-Akt) in aorta	
50	
4.3.13.2 Blood serum parameters	50
4.3.13.2.1 Fasting serum glucose (GOD-POD end point assay)	50
4.3.13.2.2 Cholesterol.....	51
4.3.13.2.3 HDL-cholesterol (CHOD/POD-Phosphotungstate method).....	51
4.3.13.2.4 Triglycerides (GPO method)	52
4.3.13.3 Urine sample analysis	53
4.3.13.3.1 Creatinine.....	53
4.3.13.3.2 Uric Acid	53
4.3.13.3.3 Sodium.....	53
4.3.13.3.4 Potassium.....	54
4.3.13.3.5 Urea	55
4.3.13.3.6 Albumin	55
4.3.13.3.7 Creatinine clearance	55
4.3.14 Estimation of oxidative stress parameters in heart and kidney homogenates	56
4.3.14.1 Total protein content.....	56
4.3.14.2 Nitric oxide	56
4.3.14.3 Malondialdehyde (MDA)	57
4.3.14.4 Reduced glutathione (GSH).....	58

4.3.14.5	Super oxide dismutase (SOD).....	58
4.3.14.6	Catalase.....	59
4.3.15	Histopathology study.....	60
4.3.16	Effect of compound (18) and (24) in 20% fructose induced Cardiometabolic disorder.....	60
4.3.16.1	Molecular docking study of compound (18) and (24) with targets of Cardiometabolic disorder.....	60
4.3.16.1.1	Protein preparation	60
4.3.16.1.2	Grid generation	61
4.3.16.1.3	Ligand preparation.....	61
4.3.16.1.4	Ligand docking with maestro	61
4.3.16.1.5	Ligand docking with AUTODOCK VINA	61
4.3.16.2	<i>In-vivo</i> activity of Compound (18) and (24) in 20% induced cardiometabolic disorder 62	
4.3.17	Collection of blood.....	63
4.3.17.1	Measurement of Hemodynamic Parameters	63
4.3.17.1.1	Invasive blood pressure measurements	63
4.3.17.2	Endothelial dysfunction	63
4.3.17.3	Blood parameters	63
4.3.17.3.1	Blood serum parameters	63
4.3.17.3.1.1	Fasting serum Glucose (GOD-POD end point assay).....	63
4.3.17.3.1.2	Oral Glucose Tolerance Test.....	63
4.3.17.3.1.3	HOMA-IR and QUICKI	64
4.3.17.3.1.4	Cholesterol	64
4.3.17.3.1.5	Triglycerides (GPO method).....	64
4.3.17.3.1.6	HDL-cholesterol (CHOD/POD-Phosphotungstate method).....	64
4.3.17.3.2	Blood plasma parameters.....	64
4.3.17.3.2.1	Insulin	64
4.3.17.3.2.2	Leptin	65
4.3.17.3.2.3	Adiponectin.....	66
4.3.18	Histopathology study.....	67
4.4	Methods for screening and evaluation of novel FXa inhibitors for anticoagulant and antithrombotic activity	67

4.4.1	<i>In-vitro</i> inhibition assay	67
4.4.1.1	<i>In-vitro</i> FXa inhibition assay	67
4.4.1.2	<i>In-vitro</i> thrombin inhibition assay	67
4.4.1.3	<i>In-vitro</i> anticoagulant activity by PT and aPTT measurement	68
4.4.2	Docking studies of novel FXa inhibitors.....	68
4.4.3	Cytotoxicity assay of compound (14) and (50) on H9C2 cardiac myocytes.....	69
4.4.4	Acute toxicity study of compound (14) and (50) according to OECD guidelines ..	69
4.4.5	<i>In-vivo</i> evaluation of antithrombotic activity of compound (14) and (50)	69
4.4.5.1	FeCl ₃ induced arterial thrombosis.....	69
4.4.5.2	Arteriovenous shunt (AV-SHUNT) induced thrombosis model	70
4.4.5.3	Tail bleeding model	71
4.5	Statistical analysis	71
5.	RESULTS AND DISCUSSION.....	72
5.1	Functional antagonism assay of standards and synthesized multitargeted ligands	72
5.1.11	Establishing baseline values for agonists and studies with standard antagonists of α_1 and AT ₁ receptor.....	72
5.1.2	Screening of potential compounds for dual antagonism of α_1 and AT ₁ receptors...	73
5.1.3	Elaborated functional antagonism assay of potent compound (18) and (24)	83
5.2	Molecular docking study of compound (18) and (24) with α_1 and AT ₁ Receptor	84
5.3	<i>In-vivo</i> pressor response evaluation of compound (18) and (24) in anesthetized rats....	86
5.3.1	Unmasked pressor response	86
5.3.2	Masked pressor response	88
5.4	Cytotoxicity assay of compound (18) and (24) in HEK293 cell	89
5.5	<i>In-silico</i> physicochemical properties of compound (18) and (24).....	90
5.5.1	Radar chart and Brain Or IntestinaL EstimatedD permeation method (Boiled-Egg) diagram of compound (18) and (24).....	93
5.6	ADME analysis and toxicity prediction of compound (18) and (24).....	94
5.7	Acute toxicity study of compound (18) and (24) according to OECD guidelines	96
5.8	Evaluation of compound (18) and (24) in UNX+DOCA salt induced hypertension	97
5.8.1	Effect of compound (18) and (24) on physiological parameters in UNX+DOCA salt induced hypertension.....	98
5.8.2	Effect of compound (18) and (24) on hypertrophic response in UNX+DOCA saltinduced hypertension	100

5.8.3 Effect of compound (18) and (24) on hemodynamic alterations in UNX+DOCA salt induced hypertension.....	101
5.8.4 Effect of (18) and (24) on articular reactivity in UNX+DOCA salt inducedhypertension 104	
5.8.5 Effect of compound (18) and (24) on metabolic parameters in UNX+DOCA salt induced hypertension.....	105
5.8.6 Effect of compound (18) and (24) on Ach mediated endothelial relaxation and nitricoxide level in UNX+DOCA salt induced hypertension	107
5.8.7 Effect of compound (18) and (24) on Protein Kinase C (PKC) and p-Akt protein expression in UNX+DOCA salt induced hypertension.....	108
5.8.8 Effect of compound (18) and (24) on cytokine imbalance in UNX+DOCA salt induced hypertension.....	110
5.8.9 Effect of compound (18) and (24) on urinary indices in UNX+DOCA salt induced hypertension	112
5.8.10 Effect on compound (18) and (24) on oxidative stress parameters in UNX+DOCA salt induced hypertension	116
5.8.10.1 Effect on compound (18) and (24) on oxidative stress parameters in heart of UNX+DOCA salt induced hypertension	116
5.8.10.2 Effect on compound (18) and (24) on oxidative stress parameters in kidney of UNX+DOCA salt induced hypertension	117
5.8.11 Effect of compound (18) and (24) on histopathological changes in UNX+DOCA salt induced hypertension	118
5.9 Evaluation of compound (18) and (24) in L-NAME induced hypertension	123
5.9.1 Effect of compound (18) and (24) on physiological parameters in L-NAME induced hypertension	123
5.9.2 Effect of compound (18) and (24) on hemodynamic parameters in L-NAME induced hypertension	124
5.9.3 Effect of compound (18) and (24) on articular reactivity in L-NAME induced hypertension	126
5.9.4 Effect of compound (18) and (24) on hypertrophic response in L-NAME induced hypertension	127
5.9.5 Effect of compound (18) and (24) on endothelial dysfunction and plasma nitric oxidelevel in L-NAME induced hypertension	129

5.9.6 Effect of compound (18) and (24) on cytokines level in L-NAME inducedhypertension	130
5.9.7 Effect of compound (18) and (24) on urinary indices in L-NAME inducedhypertension	132
5.9.8 Effect on compound (18) and (24) on oxidative stress parameters in heart of L-NAME induced hypertension	134
5.9.8.1 Effect on compound (18) and (24) on oxidative stress parameters in heart of L-NAME induced hypertension	134
5.9.8.2 Effect of compound (18) and (24) on oxidative stress parameters in kidney of L-NAME induced hypertension	135
5.9.9 Effect of compound (18) and (24) on histopathological changes in L-NAME induced hypertension	136
5.10 Evaluation of compound (18) and (24) in cardiometabolic disorders in rats	139
5.10.1 <i>In-silico</i> study of compound (18) and (24) with targets of CMets	139
5.10.1.1 <i>In-silico</i> study of compound (18) and (24) with DPP4 enzyme	139
5.10.1.2 <i>In-silico</i> study of compound (18) and (24) with PPAR γ receptor	141
5.11 Evaluation of compound (18) and (24) in 20 % fructose induced cardiometabolic disorders in rats	142
5.11.1 Effect of compound (18) and (24) on physiological parameters in 20% fructose induced CMets.....	143
5.11.2 Effect of compound (18) and (24) on metabolic parameters in 20% fructose induced CMets	144
5.11.3 Effect of compound (18) and (24) on glycemic parameters in 20% fructose induced CMets	145
5.11.4 Effect of compound (18) and (24) on hemodynamic parameters in 20% fructose induced CMets.....	149
5.11.5 Effect of compound (18) and (24) on articular reactivity in 20% fructose induced CMets	150
5.11.6 Effect of compound (18) and (24) on adipocytokines in 20% fructose induced CMets	151
5.11.7 Effect of compound (18) and (24) on liver and heart in 20% fructose induced CMets	152
5.11.8 Effect of compound (18) and (24) on histopathological changes in 20% fructose	

induced CMets.....	153
5.12 Pharmacological screening and evaluation of compound (14) and (50) for FXa inhibition	156
5.12.1 <i>In-vitro</i> FXa inhibition <i>and ex-vivo</i> assay for evaluation of antithrombotic activity	156
5.12.2 Molecular docking studies of compound (14) and (50) for FXa enzyme	167
5.12.3 Selectivity of compound (14) and (50) for FXa	168
5.12.3.1 Thrombin (FIIa) inhibition assay	168
5.12.4 Cytotoxicity assay of compound (14) and (50) in H9C2 cardiac myocytes cells.....	169
5.12.5 Physicochemical properties of compound (14) and (50).....	169
5.12.5.1 Radar chart and Brain Or IntestinaL EstimateD permeation method (Boiled-Egg) diagram of compound (14) and (50)	171
5.12.6 ADME analysis and toxicity prediction	172
5.12.7 Acute toxicity study of compound (14) and (50) according to OECD guidelines	174
5.12.8 <i>In-vivo</i> antithrombotic activity of compound (14) and (50) against FeCl ₃ induced arterial thrombosis	175
5.12.9 <i>In-vivo</i> antithrombotic activity of compound (14) and (50) in arteriovenous shunt induced thrombosis.....	176
5.12.10 Tail bleeding risk of compound (14) and (50) in tail bleeding model.....	176
6. SUMMARY AND CONCLUSION	178

LIST OF FIGURES

Sr. No.	Figure no.	Title	Page no.
1.	Figure 5.1	Concentration response curves (pA ₂ values) of standard drugs	72
2.	Figure 5.2	Concentration response curves (pA ₂ value) of compound (18) at different concentrations.	83
3.	Figure 5.3	Concentration response curves (pA ₂ value) of compound (24) at different concentrations.	84
4.	Figure 5.4	Docking interactions of compound (18) and (24) with α_1 -receptor.	84
5.	Figure 5.5	Docking interactions of compound (18) and (24) with AT ₁ -receptor.	85
6.	Figure 5.6	Effect of compound (18) and (24) against agonist induced pressor response (Unmasked condition)	87
7.	Figure 5.7	Effect of compound (18) and (24) against agonist induced pressor response (masked condition)	88
8.	Figure 5.8	Survival of cells post-incubation with different concentrations of compounds (18) and (24)	90
9.	Figure 5.9	Radar chart and Boiled Egg diagram of compound (18)	93
10.	Figure 5.10	Radar chart and Boiled Egg diagram of compound (24)	94
11.	Figure 5.11	Effect of compound (18) and (24) on hypertrophic response in UNX+DOCA salt induced hypertension	100
12.	Figure 5.12	Effect of compound (18) and (24) on hemodynamic alterations in UNX+DOCA salt induced hypertension.	101
13.	Figure 5.13	Effect of compound (18) and (24) on Ach mediated endothelial relaxation and nitric oxide level in UNX+DOCA salt induced hypertension.	107
14.	Figure 5.14	Effect of compound (18) and (24) on PKC expression in aorta of DOCA salt hypertensive rats.	109
15.	Figure 5.15	Effect of compound (18) and (24) on p-Akt expression in aorta of DOCA salt hypertensive rats.	109
16.	Figure 5.16	Effect of compound (18) and (24) on oxidative stress parameters in heart of UNX+DOCA salt induced hypertension.	116

Sr. No.	Figure no.	Title	Page no.
17.	Figure 5.17	Effect of compound (18) and (24) on oxidative stress parameters in kidney of UNX+DOCA salt induced hypertension.	117
18.	Figure 5.18	Effect of compound (18) and (24) on histopathological changes (heart) in UNX+DOCA salt induced hypertension in H&E Staining	119
19.	Figure 5.19	Effect of compound (18) and (24) on histopathological changes (kidney) in UNX+DOCA salt induced hypertension in H&E Staining	120
20.	Figure 5.20	Effect of compound (18) and (24) on histopathological changes in kidney by UNX+DOCA salt induced hypertension by PAS staining.	121
21.	Figure 5.21	Effect of compound (18) and (24) on histopathological changes (Aorta) in UNX+DOCA salt induced hypertension in H&E Staining	122
22.	Figure 5.22	Effect of compound (18) and (24) on hemodynamic parameters in L-NAME induced hypertension.	124
23.	Figure 5.23	Effect of compound (18) and (24) on hypertrophic response in L-NAME induced Hypertension	127
24.	Figure 5.24	Effect of compound (18) and (24) on Endothelial dysfunction and Plasma nitric oxide level in L-NAME induced hypertension	129
25.	Figure 5.25	Effect of compound (18) and (24) on oxidative stress parameters in heart of L-NAME induced hypertension.	134
26.	Figure 5.26	Effect of compound (18) and (24) on oxidative stress parameters in kidney of L-NAME induced hypertension.	135
27.	Figure 5.27	Effect of compound (18) and (24) on histopathological changes in heart by L-NAME induced hypertension in H&E staining.	136
28.	Figure 5.28	Effect of compound (18) and (24) on histopathological changes in kidney by L-NAME induced hypertension in H&E staining.	137

Sr. No.	Figure no.	Title	Page no.
29.	Figure 5.29	Effect of compound (18) and (24) on histopathological changes in aorta by L-NAME induced hypertension in H&E staining.	138
30.	Figure 5.30	Binding site of molecules on (A) DPP4 and (B) PPAR γ .	139
31.	Figure 5.31	Interactions of (A) compound (18) and (B) compound (24) with the DPP4.	140
32.	Figure 5.32	Interactions of (A) compound (18) and (B) compound (24) with the PPAR γ .	141
33.	Figure 5.33	Effect of compound (18) and (24) on metabolic parameters in 20% fructose induced CMets.	144
34.	Figure 5.34	Effect of compound (18) and (24) on glycemic parameters in 20% fructose induced CMets.	145
35.	Figure 5.35	Effect of compound (18) and (24) on insulin sensitivity index by HOMA-IR.	147
36.	Figure 5.36	Effect of compound (18) and (24) on insulin sensitivity index by QUICKI.	148
37.	Figure 5.37	Effect of compound (18) and (24) on hemodynamic parameters in 20% fructose induced CMets.	149
38.	Figure 5.38	Effect of compound (18) and (24) on articular reactivity in 20% fructose induced CMets.	150
39.	Figure 5.39	Effect of compound (18) and (24) on adipocytokines in 20% fructose induced CMets.	151
40.	Figure 5.40	Effect of compound (18) and (24) on liver and heart in 20% fructose induced CMets.	152
41.	Figure 5.41	Effect of compound (18) and (24) on histopathological changes in liver by 20% fructose induced CMets.	153
42.	Figure 5.42	Effect of compound (18) and (24) on histopathological changes in pancreas by 20% fructose induced CMets.	154
43.	Figure 5.43	Effect of compound (18) and (24) on histopathological changes in adipose tissue by 20% fructose induced CMets.	155
44.	Figure 5.44	Docking pose and representation of interactions between compounds (A) (14) and (B) (50) and the active site of FXa enzyme.	167
45.	Figure 5.45	Survival of cells post-incubation with different concentrations of compounds (14) , (50)	169

Sr. No.	Figure no.	Title	Page no.
46.	Figure 5.46	Radar chart and Boiled Egg diagram of compound (14)	171
47.	Figure 5.47	Radar chart and Boiled Egg diagram of compound (50)	171
48.	Figure 5.48	Effect of compound (14) , (50) and apixaban on thrombus weight (FeCl ₃ induced arterial thrombosis model).	175
49.	Figure 5.49	Effect of compound (14) , (50) and apixaban on thrombus weight (AV shunt induced thrombosis model).	176
50.	Figure 5.50	Effect of compound (14) , (50) and apixaban on bleeding time.	176

LIST OF TABLES

Sr. No.	Table no.	Heading	Page no.
1.	Table 4.1	Evaluation of compound (18) and (24) in UNX+DOCA salt induced hypertension in rats	44
2.	Table 4.2	Evaluation of compound (18) and (24) in L-NAME induced hypertension in rats	45
3.	Table 4.3	Experimental design for compound (18) and (24) in 20% induced cardiometabolic disorder	62
4.	Table 4.4	Effect of compound (14) and (50) in FeCl ₃ induced thrombosis in rats	70
5.	Table 4.5	Effect of compound (14) and (50) in Arteriovenous shunt induced thrombosis in rats	71
6.	Table 5.1	pA ₂ value of compounds of series I	74
7.	Table 5.2	pA ₂ value of compounds of series II	75
8.	Table 5.3	pA ₂ value of compounds of series III	76
9.	Table 5.4	pA ₂ value of compounds of series IV	77
10.	Table 5.5	pA ₂ value of compounds of series V	78
11.	Table 5.6	pA ₂ value of compounds of series VI	79
12.	Table 5.7	pA ₂ value of compounds of series VII	80
13.	Table 5.8	pA ₂ value of compounds of series VIII	81
14.	Table 5.9	pA ₂ value of compounds of series IX	81
15.	Table 5.10	Physicochemical properties of compound (18) and (24) by SWISS ADME	91
16.	Table 5.11	ADME analysis and toxicity prediction of compound (18) and (24)	94
17.	Table 5.12	Effect of compound (18) and (24) on physiological parameters in UNX+DOCA salt induced hypertension	98
18.	Table 5.13	Articular reactivity of compound (18) and (24) in UNX+DOCA salt induced hypertension	104
19.	Table 5.14	Effect of compound (18) and (24) on metabolic parameters in UNX+DOCA salt induced Hypertension	106
20.	Table 5.15	Effect of compound (18) and (24) on cytokine levels in UNX+DOCA salt induced hypertension	110
21.	Table 5.16	Effect of compound (18) and (24) on urinary parameters in UNX+DOCA salt induced Hypertension	112
22.	Table 5.17	Effect of compound (18) and (24) on physiological parameters in L-NAME induced hypertension	123

Sr. No.	Table no.	Heading	Page no.
23.	Table 5.18	Articular reactivity of compound (18) and (24) in L-NAME induced hypertension	126
24.	Table 5.19	Effect of compound (18) and (24) on cytokines level in L-NAME induced hypertension	130
25.	Table 5.20	Effect of compound (18) and (24) on urinary indices in L-NAME induced hypertension	132
26.	Table 5.21	Effect of compound (18) and (24) on physiological parameters in 20% fructose induced CMets	143
27.	Table 5.22	IC ₅₀ values, PT and aPTT time of compounds (1-17)	157
28.	Table 5.23	IC ₅₀ values, PT and aPTT time of compounds (18-23)	159
29.	Table 5.24	IC ₅₀ values, PT and aPTT time of compounds (24-30)	160
30.	Table 5.25	IC ₅₀ values, PT and aPTT time of compounds (31-39)	161
31.	Table 5.26	IC ₅₀ values, PT and aPTT time of compounds (40-52)	162
32.	Table 5.27	IC ₅₀ values, PT and aPTT time of compounds (53-66)	163
33.	Table 5.28	IC ₅₀ values, PT and aPTT time of compounds (67-78)	165
34.	Table 5.29	Physicochemical properties of compound (14) and (50)	170
35.	Table 5.30	ADME and toxicity prediction of compound (14) and (50)	173

List of Abbreviations

Abbreviation	Full form
CMets	Cardiometabolic disorders
IR	Insulin Resistance
ASCVDs	Atherosclerotic Cardiovascular Diseases
WHO	World Health Organization
CVD	Cardiovascular Diseases
ACC/AHA	American College of Cardiology / American Heart Association
BP	Blood pressure
RAAS	Renin Angiotensin Aldosterone System
SNS	Sympathetic nervous system
Ang II	Angiotensin II
ACE	Angiotensin converting enzyme
HTN	Hypertension
PK-PD	Pharmacokinetic pharmacodynamic
DML	Designed multitargeted ligands
AT ₁	Angiotensin type-1 receptor
MetS	Metabolic disorders
VTE	Venous thromboembolism
TG	Triglyceride
LDL	Low density lipoprotein
HDL	High density lipoprotein
TC	Total cholesterol
FXa	Factor Xa / Stuart factor
FIIa	Thrombin
VKAs	Vitamin K antagonists
UFH	Unfractionated heparin
LMWHs	Low-molecular-weight heparins
NCE	New chemical entity
DPP4	Dipeptidyl peptidase-4 inhibitor
PPAR γ	Peroxisome proliferator-activated receptor gamma
ADMET	Absorption, distribution, metabolism, excretion and toxicity
OECD	Organization for Economic Co-operation and Development
UNX	Unilateral Nephrectomy
DOCA	Deoxycorticosterone acetate
L-NAME	L-Nitro Arginine Methyl Ester
PT	Prothrombin time

Abbreviation	Full form
aPTT	Activated partial thromboplastin
AV shunt	Arteriovenous shunt
TNF- α	Tumor Necrosis Factor alpha
IL-6	Interleukin 6
ELISA	Enzyme-linked immunosorbent assay
NCCS	National Centre for Cell Science
DMEM	Dulbecco's minimum essential medium
EDTA	Ethylenediamine tetraacetic acid
MTT	3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium Bromide
RO	Reverse osmosis
IAEC	Institutional Animal Ethics Committee
CPCSEA	Committee for the Purpose of Control and Supervision of Experiments on Animals
PE	Polyethylene
DMSO	Dimethyl sulfoxide
ANOVA	Analysis of variance
HTVS	High-throughput virtual screening
SP	Standard precision
XP	Extra precision
PBS	Phosphate buffer saline
ADME	Absorption, distribution, metabolism and excretion
OD	Optical density
TPSA	Topological polar surface area
nRotb	Number of rotatable bonds
NaCMC	Sodium carboxymethyl cellulose
UV	Ultraviolet
HRP	Horseradish peroxidase
PKC	Protein Kinase C
p-Akt	Phospho-Akt / Protein kinase B
GOD-POD	Glucose oxidase-peroxidase
GPO	Glycerol phosphate oxidase
OPA	Ortho-phosphoric acid
NEDA	Naphthyl ethylenediamine dihydrochloride
MDA	Malondialdehyde
TCA	Trichloroacetic acid

Abbreviation	Full form
TBA	Thiobarbituric acid
GSH	Reduced glutathione
DTNB	5, 5'-dithiobis (2-nitro benzoic acid)
SOD	Superoxide Dismutase
HOMA-IR	Homeostasis model assessment-estimated insulin resistance
QUICKI	Quantitative insulin sensitivity check index
CRC	Concentration response curve
MABP	Mean arterial blood pressure
3D-QSAR	Three-dimensional quantitative structure-activity relationships
MTDL	Multi targeted directed ligands
Pgp	P-glycoprotein
BBB	Blood–brain barrier
CNS	Central nervous system
CYPs	Cytochrome P450
OCT2	Organic Cation Transporter 2
ROS	Reactive oxygen species
NC	Normal control
SC	Sham control
DC	Disease control
KW/BW	Kidney weight/Body weight
KOI	Kidney Oedema Index
ARB	Angiotensin receptor blockers
HOI	Heart Oedema Index
SBP	Systolic blood pressure
DBP	Diastolic blood pressure
HDL-C	High-density lipoprotein cholesterol
VSM	Vascular smooth muscle
MAPK	Mitogen-activated protein kinase
eNOS	Endothelial nitric oxide synthase
NADPH	Nicotinamide adenine dinucleotide phosphate
Los	Losartan
Tera	Terazosin
NO	Nitric oxide
NF-kB	Nuclear factor kappa B
HD	Hypercaloric diet
MS	Metabolic syndrome

Abbreviation	Full form
LBD	Ligand binding domain
Ach	Acetylcholine
OGTT	Oral glucose tolerance test
RCSB	Research Collaboratory for Structural Bioinformatics
LOAEL	Lowest observed adverse effect level
VEC	Vascular endothelial cells